Peptide Reports

MOTS-c

Community Protocol

MOTS-c

Reconstitution examples, syringe conversion and community-reported usage patterns.

Educational and calculation-reference material only. Community reports are uncontrolled anecdotes and do not replace professional medical guidance, product labeling, or individualized clinical monitoring.

Scope

Reconstitution examples, syringe conversion and community-reported usage patterns.

Available strengths: 10 MG and 40 MG

Preparation Examples

These are calculation examples only. The concentration assumptions below are explicit so syringe units are never separated from vial strength and diluent volume.

SetupDiluentConcentrationUnit conversion
10 MG vial exampleAdd 2.0 mL bacteriostatic water5 mg/mLEach U-100 unit = 0.05 mg
40 MG vial exampleAdd 2.0 mL bacteriostatic water20 mg/mLEach U-100 unit = 0.20 mg

Syringe Conversion

Reported amount10 MG setup40 MG setup
1 mg20 units5 units
2 mg40 units10 units
3 mg60 units15 units
5 mg100 units25 units

Always recalculate from the actual vial strength and diluent volume. A U-100 unit is 0.01 mL; it is not a dose by itself.

Community-Reported Patterns

Recurring reportFrequency seenContext in reports
2 mgEvery other day or 3-5 days/weekGeneral metabolic or training use
3 mgBefore activity or 5 days/weekEnergy and endurance reports
5 mg3-4 days/weekHigher-dose cycle reports

Observations

  • Community reports span approximately 2-5 mg per administration; frequency varies substantially.
  • Several contributors stressed recording active amount in mg rather than syringe units.
  • Reported cycles commonly included breaks, but duration and break length were inconsistent.

Caveats

  • Posts contained conflicting claims about stability after reconstitution; follow the dispensing pharmacy's storage and beyond-use directions.
  • Reported experiences included changes in energy, exercise tolerance and resting heart rate, but these anecdotes do not establish causation.

Sources

  1. r/Peptides, MOTS-c dosing
  2. r/Peptidesource, MOTS-C
  3. r/PeptidePathways, MOTS-C dosing